Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: a retrospective cohort study

  1. James A Hay
  2. Stephen M Kissler
  3. Joseph R Fauver
  4. Christina Mack
  5. Caroline G Tai
  6. Radhika M Samant
  7. Sarah Connolly
  8. Deverick J Anderson
  9. Gaurav Khullar
  10. Matthew MacKay
  11. Miral Patel
  12. Shannan Kelly
  13. April Manhertz
  14. Isaac Eiter
  15. Daisy Salgado
  16. Tim Baker
  17. Ben Howard
  18. Joel T Dudley
  19. Christopher E Mason
  20. Manoj Nair
  21. Yaoxing Huang
  22. John DiFiori
  23. David D Ho
  24. Nathan Grubaugh  Is a corresponding author
  25. Yonatan H Grad  Is a corresponding author
  1. Harvard TH Chan School of Public Health, United States
  2. Yale School of Public Health, United States
  3. IQVIA, United States
  4. Duke Center for Antimicrobial Stewardship and Infection Prevention, United States
  5. Tempus Labs, United States
  6. Columbia University, United States
  7. Hospital for Special Surgery, United States

Abstract

Background: The combined impact of immunity and SARS-CoV-2 variants on viral kinetics during infections has been unclear.

Methods: We characterized 1,280 infections from the National Basketball Association occupational health cohort identified between June 2020 and January 2022 using serial RT-qPCR testing. Logistic regression and semi-mechanistic viral RNA kinetics models were used to quantify the effect of age, variant, symptom status, infection history, vaccination status and antibody titer to the founder SARS-CoV-2 strain on the duration of potential infectiousness and overall viral kinetics. The frequency of viral rebounds was quantified under multiple cycle threshold (Ct) value-based definitions.

Results: Among individuals detected partway through their infection, 51.0% (95% credible interval [CrI]: 48.3-53.6%) remained potentially infectious (Ct<30) five days post detection, with small differences across variants and vaccination status. Only seven viral rebounds (0.7%; N=999) were observed, with rebound defined as 3+ days with Ct<30 following an initial clearance of 3+ days with Ct≥30. High antibody titers against the founder SARS-CoV-2 strain predicted lower peak viral loads and shorter durations of infection. Among Omicron BA.1 infections, boosted individuals had lower pre-booster antibody titers and longer clearance times than non-boosted individuals.

Conclusions: SARS-CoV-2 viral kinetics are partly determined by immunity and variant but dominated by individual-level variation. Since booster vaccination protects against infection, longer clearance times for BA.1-infected, boosted individuals may reflect a less effective immune response, more common in older individuals, that increases infection risk and reduces viral RNA clearance rate. The shifting landscape of viral kinetics underscores the need for continued monitoring to optimize isolation policies and to contextualize the health impacts of therapeutics and vaccines.

Funding: Supported in part by CDC contract #200-2016-91779, a sponsored research agreement to Yale University from the National Basketball Association contract #21-003529, and the National Basketball Players Association.

Data availability

All code and data required to reproduce the analyses are available at https://github.com/gradlab/SC2-kinetics-immune-history.

Article and author information

Author details

  1. James A Hay

    Harvard TH Chan School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1998-1844
  2. Stephen M Kissler

    Harvard TH Chan School of Public Health, Boston, United States
    Competing interests
    Stephen M Kissler, SMK has a consulting agreement with the NBA.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3062-7800
  3. Joseph R Fauver

    Yale School of Public Health, New Haven, United States
    Competing interests
    Joseph R Fauver, has a consulting agreement for Tempus and receives financial support from Tempus to develop SARS-CoV-2 diagnostic tests.
  4. Christina Mack

    IQVIA, Durham, United States
    Competing interests
    Christina Mack, is an employee of IQVIA, Real World Solutions.
  5. Caroline G Tai

    IQVIA, Durham, United States
    Competing interests
    Caroline G Tai, is an employee of IQVIA, Real World Solutions.
  6. Radhika M Samant

    IQVIA, Durham, United States
    Competing interests
    Radhika M Samant, is an employee of IQVIA, Real World Solutions.
  7. Sarah Connolly

    IQVIA, Durham, United States
    Competing interests
    Sarah Connolly, is an employee of IQVIA, Real World Solutions.
  8. Deverick J Anderson

    Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, United States
    Competing interests
    Deverick J Anderson, is co-owner of Infection Control Education for Major Sports.
  9. Gaurav Khullar

    Tempus Labs, Chicago, United States
    Competing interests
    Gaurav Khullar, is an employee of Tempus Labs.
  10. Matthew MacKay

    Tempus Labs, Chicago, United States
    Competing interests
    Matthew MacKay, is an employee of Tempus Labs.
  11. Miral Patel

    Tempus Labs, Chicago, United States
    Competing interests
    Miral Patel, is an employee of Tempus Labs.
  12. Shannan Kelly

    Tempus Labs, Chicago, United States
    Competing interests
    Shannan Kelly, is an employee of Tempus Labs.
  13. April Manhertz

    Tempus Labs, Chicago, United States
    Competing interests
    April Manhertz, is an employee of Tempus Labs.
  14. Isaac Eiter

    Tempus Labs, Chicago, United States
    Competing interests
    Isaac Eiter, is an employee of Tempus Labs.
  15. Daisy Salgado

    Tempus Labs, Chicago, United States
    Competing interests
    Daisy Salgado, is an employee of Tempus Labs.
  16. Tim Baker

    Tempus Labs, Chicago, United States
    Competing interests
    Tim Baker, is an employee of Tempus Labs.
  17. Ben Howard

    Tempus Labs, Chicago, United States
    Competing interests
    Ben Howard, is an employee of Tempus Labs.
  18. Joel T Dudley

    Tempus Labs, Chicago, United States
    Competing interests
    Joel T Dudley, is an employee of Tempus Labs.
  19. Christopher E Mason

    Tempus Labs, Chicago, United States
    Competing interests
    Christopher E Mason, is an employee of Tempus Labs.
  20. Manoj Nair

    Vagelos College of Physicians and Surgeons, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5994-3957
  21. Yaoxing Huang

    Vagelos College of Physicians and Surgeons, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  22. John DiFiori

    Hospital for Special Surgery, New York, United States
    Competing interests
    John DiFiori, is an employee of the NBA.
  23. David D Ho

    Vagelos College of Physicians and Surgeons, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  24. Nathan Grubaugh

    Yale School of Public Health, New Haven, United States
    For correspondence
    grubaughlab@gmail.com
    Competing interests
    Nathan Grubaugh, has a consulting agreement for Tempus and receives financial support from Tempus to develop SARS-CoV-2 diagnostic tests.
  25. Yonatan H Grad

    Harvard TH Chan School of Public Health, Boston, United States
    For correspondence
    ygrad@hsph.harvard.edu
    Competing interests
    Yonatan H Grad, has a consulting agreement with the NBA.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5646-1314

Funding

Centers for Disease Control and Prevention (200-2016-91779)

  • Yonatan H Grad

National Basketball Association (21-003529)

  • Nathan Grubaugh

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Isabel Rodriguez-Barraquer, University of California, San Francisco, United States

Version history

  1. Preprint posted: January 14, 2022 (view preprint)
  2. Received: July 13, 2022
  3. Accepted: November 15, 2022
  4. Accepted Manuscript published: November 16, 2022 (version 1)
  5. Version of Record published: November 30, 2022 (version 2)

Copyright

© 2022, Hay et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,391
    views
  • 330
    downloads
  • 53
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. James A Hay
  2. Stephen M Kissler
  3. Joseph R Fauver
  4. Christina Mack
  5. Caroline G Tai
  6. Radhika M Samant
  7. Sarah Connolly
  8. Deverick J Anderson
  9. Gaurav Khullar
  10. Matthew MacKay
  11. Miral Patel
  12. Shannan Kelly
  13. April Manhertz
  14. Isaac Eiter
  15. Daisy Salgado
  16. Tim Baker
  17. Ben Howard
  18. Joel T Dudley
  19. Christopher E Mason
  20. Manoj Nair
  21. Yaoxing Huang
  22. John DiFiori
  23. David D Ho
  24. Nathan Grubaugh
  25. Yonatan H Grad
(2022)
Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: a retrospective cohort study
eLife 11:e81849.
https://doi.org/10.7554/eLife.81849

Share this article

https://doi.org/10.7554/eLife.81849

Further reading

    1. Epidemiology and Global Health
    Xiaoxin Yu, Roger S Zoh ... David B Allison
    Review Article

    We discuss 12 misperceptions, misstatements, or mistakes concerning the use of covariates in observational or nonrandomized research. Additionally, we offer advice to help investigators, editors, reviewers, and readers make more informed decisions about conducting and interpreting research where the influence of covariates may be at issue. We primarily address misperceptions in the context of statistical management of the covariates through various forms of modeling, although we also emphasize design and model or variable selection. Other approaches to addressing the effects of covariates, including matching, have logical extensions from what we discuss here but are not dwelled upon heavily. The misperceptions, misstatements, or mistakes we discuss include accurate representation of covariates, effects of measurement error, overreliance on covariate categorization, underestimation of power loss when controlling for covariates, misinterpretation of significance in statistical models, and misconceptions about confounding variables, selecting on a collider, and p value interpretations in covariate-inclusive analyses. This condensed overview serves to correct common errors and improve research quality in general and in nutrition research specifically.

    1. Ecology
    2. Epidemiology and Global Health
    Emilia Johnson, Reuben Sunil Kumar Sharma ... Kimberly Fornace
    Research Article

    Zoonotic disease dynamics in wildlife hosts are rarely quantified at macroecological scales due to the lack of systematic surveys. Non-human primates (NHPs) host Plasmodium knowlesi, a zoonotic malaria of public health concern and the main barrier to malaria elimination in Southeast Asia. Understanding of regional P. knowlesi infection dynamics in wildlife is limited. Here, we systematically assemble reports of NHP P. knowlesi and investigate geographic determinants of prevalence in reservoir species. Meta-analysis of 6322 NHPs from 148 sites reveals that prevalence is heterogeneous across Southeast Asia, with low overall prevalence and high estimates for Malaysian Borneo. We find that regions exhibiting higher prevalence in NHPs overlap with human infection hotspots. In wildlife and humans, parasite transmission is linked to land conversion and fragmentation. By assembling remote sensing data and fitting statistical models to prevalence at multiple spatial scales, we identify novel relationships between P. knowlesi in NHPs and forest fragmentation. This suggests that higher prevalence may be contingent on habitat complexity, which would begin to explain observed geographic variation in parasite burden. These findings address critical gaps in understanding regional P. knowlesi epidemiology and indicate that prevalence in simian reservoirs may be a key spatial driver of human spillover risk.